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Aims: International statistics show that relapse rates associated with opiate and crack 
cocaine (OCC) misuse remain high. This has led to an increased scientific interest in the 
topic of relapse. However, there are limited studies reflecting on the state of this field. 
This review provides an overview of the topic and directions for future research. 
Method: Guided by the overall question of how relapse into OCC misuse is understood, 
a scoping review was conducted using Arksey and O’Malley’s framework. A total of 126 
studies between 1972 and 2019 were included. The literature was thematically grouped 
into relapse definitions, theories, associated factors and treatment approaches. Results: 
This review found that the majority of relapse understandings were derived from the 
USA and UK, and that these studies predominantly used quantitative research designs. 
Relapse definitions were controversial with the majority using biomedical concepts of 
disease. Theories on relapse were based on psychological theories and developed through 
clinical and neuroscientific research. Findings show that the majority of the literature 
focussed on relapse risk factors with very few papers focussing on protective factors. 
Findings on treatment approaches indicate a steer towards harm-minimization strategies 
over relapse management strategies. Conclusions: This review demonstrates that drug 
relapse research needs to grow more diverse, inter-disciplinary and user-centred in 











Despite ongoing efforts by policymakers and practitioners to reduce levels of 
addiction, international statistics demonstrate that drug overdose death remains a global issue 
(European Monitoring Centre for Drugs and Drug Addiction 2019). Previous research has 
demonstrated that overdose is linked to relapse (Oliver and Keen, 2003; Kariisa et al., 2019). 
Scholars distinguish between a lapse and a relapse, whereby the former implies an initial 
resumption and the latter a continued resumption (to the point of pre-treatment levels) of drug 
using behaviour after a quit attempt (Gossop et al., 2002; Steckler et al., 2013). During 
periods of quit attempts, a person’s tolerance to their drug of abuse drops. Depending on the 
dosage or purity of the substance, and whether this exceeds a person’s tolerance level, relapse 
may have fatal consequences. It is evidenced that between 50-80% of those recovering from 
class A drugs (e.g. opiates or cocaine) relapse within twelve months of treatment (Pasareanu, 
et al., 2016). 
The frequency of relapse has placed serious demands on drug policymakers and 
practitioners which has led to relapse being studied in several countries. For instance, in the 
USA, Canada and the UK has relapse been researched through prospective and retrospective 
clinical trials, as well as through real time assessments (McKay et al., 2006; Adinoff et al., 
2016). However, whilst several reviews on drug and alcohol relapse exist (Dejong, 1994; 
Carroll, 1996; Drummond, 2001; Kantak, 2003; Bradizza et al., 2006; Doukas and Cullen, 
2010; Donovan and Witkiewitz, 2012; Bailey and Husbands, 2014; Christiansen et al., 2015; 
Moeller and Paulus, 2018), only one of these (Bossert et al., 2005) has focussed on heroin 
and cocaine relapse. 
Despite this scope of knowledge, drug overdose death rates as well as relapse rates 
associated with opiates and crack cocaine (OCC) misuse remain high. Therefore, a review 
and reflection of the current evidence base is timely. The purpose of this review is to offer 
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clarity and direction for future research by scoping the literature on human relapse into OCC 
misuse. In doing so, the review will highlight where current research attention is focused and 
where relevant gaps remain. This is imperative to advancing the field and informing future 
research.  
Method  
In keeping with the purpose mentioned above, a scoping review was conducted. 
Scoping reviews are most suitable for reporting the ‘extent, variety and characteristics’ 
(O’Donovan et al., 2019, p. 4) of the available evidence, especially when the ‘research field is 
fragmented across several disciplines’ (Callegari et al., 2019, p. 3). Unlike systematic 
reviews, scoping reviews do not seek to assess the quality of the evidence but aim to map the 
range of available research findings (Peters et al., 2015). Arksey and O’Malley’s (2005) five-
stage method for scoping reviews was employed, which allows for a rigorous search and 
analysis of the literature regarding the chosen aims, objectives and overall review questions.  
Stage one: review questions, aims and objectives 
This scoping review was guided by the overall question of how human relapse into 
OCC misuse is understood in the current literature, pertaining to relapse definitions, theories 
and treatment approaches. In accordance with the scoping review method, this broad question 
does not require specific definitions of the population and context, meaning that evidence on 
OCC users of any age, gender, socio-economic status or geographical background were 
considered. 
By answering the above question, the review aimed to: 
1. provide an overview of relapse understandings in the existing literature 
2. highlight research trends within the literature 
3. illuminate any gaps in the evidence base  
4. provide recommendations for future research 
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Stage two: identification of relevant studies 
Given Arksey and O’Malley’s (2005) emphasis on searching a variety of sources, the 
initial search, conducted in February 2019, utilized four electronic databases and seven peer-
reviewed journals in the field. This search yielded 5,178 hits and can be examined in Table 1 
below. The search was restricted to peer-reviewed literature published in English (due to 
limited translation services). Subject restrictions were kept to a minimum in order to consider 
literature from the social, health and life sciences. No limit was set on time period, study 
design and methodology. 
[Table 1 near here] 
Stage three: literature selection 
In this stage, titles and abstracts were screened for relevance by using designated 
inclusion and exclusion criteria. Abstracts which signalled a focus on drugs other than OCC 
(e.g. ketamine) were excluded so as to keep to the central question of the review. However, 
studies were included if they investigated a topic in relation to OCC use (e.g. mental health 
and heroin addiction) or the use of other drugs with OCC (e.g. alcohol and cocaine users). 
This is because people with drug misuse issues, and particularly those using opiates and 
psychostimulants, often use more than one drug or substitute one drug for another (Bailey 
and Husbands, 2014). Further, literature which focussed on brain simulations or which used 
non-human primates as study subjects were excluded, given that the focus of the review was 
on human relapse understandings. After these criteria were applied, a total of 413 pieces of 
literature remained. Of the 413 studies selected, 69 were duplicates which left 344 pieces of 
literature for full-text screening. Some works may have been missed in the initial search due 
to the key words used, or because the electronic databases were incomplete or had not been 
updated at the time of the search. Therefore, relevant literature was also identified through 
ongoing hand searches of reference lists and bibliographies of included articles. This process 
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yielded an additional seven studies. As shown in Figure 1, the full-text screening process and 
simultaneous hand search left a total of 126 pieces of peer-reviewed literature to be included 
in the review. 
[Figure 1 near here] 
Stage four: charting the review data 
This stage produced the main source of data for the subsequent analysis. The Arksey 
and O’Malley (2005) framework provided a structure for this process. Data was charted 
(extracted) on a Microsoft Excel spreadsheet and structured so as to reflect the general 
characteristics of included studies as well as the review question identified in stage one. 
Therefore, two sets of variables were charted: firstly, generic variables (e.g. year of 
publication) and secondly, more specific information regarding the review questions (e.g. 
relapse definitions). While the former set of variables offered an overview of the distribution 
and scope of the literature, the latter set provided the data for the subsequent thematic 
analysis. A synthesized form of the data charting sheet can be viewed in Table 2 below. 
[Table 2 near here] 
Results 
Stage five: collating, summarizing and reporting 
In this section, the analysed data is reported numerically and thematically, thereby 
directly answering the overarching review question. First, the general characteristics of the 
reviewed literature are presented which comprise geographic coverage, publication trends, 
research design and topic coverage. Second, the four key themes which emerged through the 
thematic analysis are presented. These themes were: 1) definitions; 2) theories; 3) associated 
factors; and 4) treatment approaches. 
Characteristics of the literature 
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The literature included book chapters (n=5), books (n=1) and journal articles (n=120) 
of which 83 studies were retrieved from the Web of Science database. The majority of the 
remaining journal articles were retrieved from the Addiction journal (n=6). The drug under 
investigation varied in the included literature, with 37 studies investigating opiate relapse, 
and with 20 of these studies examining relapse into heroin misuse only. Thirty-three studies 
investigated psychostimulants, of which 29 examined relapse into cocaine misuse only. 
Further, seven studies investigated relapse into more than one drug (e.g. alcohol and cocaine) 
and 29 studies did not make this information explicit (e.g. they examined 'illicit drugs' or 
people with 'substance use disorder'). Only one study examined relapse into crack cocaine use 
(Wallace, 1992). The included studies originated from a total of 19 countries, of which the 
majority represented North America (n=78) with the leading country being the USA (n=76). 
The next most common region was Europe (n=30), of which most literature came from the 
UK (n=12) and the Netherlands (n=7), and then the region of Asia (n=16), within which 
China (n=7) and Iran (n=4) were the most represented countries. There was limited literature 
from South America and Africa, with only one study covering Brazil and one focussing on 
Ghana.  
Within the included literature, no study was published prior to 1972 and only one 
study was published in the 1970s (Goldstein, 1972). Figure 2 shows that the publication trend 
for relapse literature has nearly doubled every ten years since 1972, with the largest increase 
having been in the last decade (55%).  
 [Figure 2 near here] 
In 62% of the reviewed studies, relapse was investigated through quantitative, 
prospective research designs. Of these studies, the most frequently employed designs were 
prospective controlled trials (51 studies) through which data was collected using cognitive 
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assessments/interventions, such as the Cocaine Stroop task1, or functional magnetic 
resonance imaging (fMRI). The second most common type of literature were ‘non-
traditional’ research studies (19%). These included commentaries, critiques, discussions or 
case reports. Document analyses, such as literature reviews, made up the third largest 
proportion of research designs (14%). Surprisingly, only one systematic review on opiate and 
cocaine relapse was located (Dominguez-Salas et al., 2016). Finally, four studies employed 
qualitative designs and two studies provided mixed-method analyses. The four qualitative 
studies used individual interviews to investigate the following topics: relapse prevention 
strategies of poly-drug service users in Ghana (Appiah et al., 2018); relapse prevention 
strategies of street users in Scotland (McIntosh & McKeganey, 2002); perceived withdrawal 
symptoms (McAuliffe, 1982); and heroin use amongst men in mid-life (Mullen & 
Hammersley, 2006). No study included in this review was co-constructed or used 
participatory research designs. This shows that we know much more ‘about’ than ‘directly 
from’ those who have experienced relapse. 
Research in the field focussed on the following four topics: associated factors, and 
how relapse can be predicted (n=68); treatment, and how relapse can be prevented (n=48); 
theories, and how relapse has been conceptualized (n=27); and lastly, how relapse has been 
defined (n=3). As some of the studies covered more than one topic, the count of 126 
increased to a total of 147. Given that 47% of the studies covered associated factors and 33% 
covered treatment, an interest in how to predict and prevent relapse can be seen to dominate 
the literature.  
Key themes 
 
1 Stroop tasks assess for cognitive control, specifically, for attentional bias and salience attributed to 
the drug. Participants are shown words in coloured font. The task is to name the word, not the colour 
of the word, as quickly as possible (see Smith and Ersche, 2014). 
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Theme one: definitions. Definitions of relapse vary and remain controversial within 
research and practice. This may explain why only 35 studies out of the 102 studies examined 
have made their working definitions of relapse explicit (see Table 2). Bradizza et al. (2006) 
note that working definitions, where made explicit, either focussed on time (e.g. time until 
first drug use; time to first heavy drug use; number of days until four consecutive days of 
drug use) or frequency of using behaviour (e.g. number of relapse events occurring in a 
specific time interval). This variance has created tensions between scholars in the field. Some 
authors (Brown, 1988; McKay et al., 2006) have argued that having to choose from a variety 
of working definitions can lead to different research outcomes and, consequently, can create 
ambiguous evidence. Consequently, they recommend the use of one overarching relapse 
definition in research and practice.  
While relapse definitions are debated in the research context, this is not the case in 
clinical practice where relapse has predominantly been defined in one way, namely, as part of 
a substance-use disorder (McLellan et al., 2000). For instance, the governing body of 
addictions research and treatment in the US, the National Institute on Drug Abuse (NIDA), 
defines relapse as ‘the return to drug use after an attempt to stop’ (2018). This definition was 
adopted because NIDA compared drug relapse to that of other chronic health conditions, such 
as asthma and hypertension (McLellan et al., 2000). Studies revealed that this way of 
conceptualising relapse has also been integrated into practice and research in the UK (Best 
and Lubman, 2012). However, some scholars (Brown, 1998; Flynn and Brown, 2015) have 
argued against ‘normalising’ relapse as being a chronic part of the addiction disease, as it 
could create relapse as a default-and-no-fault-state and leave ‘client and program…equally 
powerless to do battle with the fates’ (p. 2518). Brown (1998) has argued that this 
terminology undermines the efforts of service users who have been able to significantly 
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reduce their drug use following a relapse. In summary, a lack of agreement about whose 
relapse definition should be adopted, remains. 
Theme two: theories. Theories on relapse for opiates and cocaine have developed 
from those of alcohol and nicotine (Marlatt and Gordon, 1985; Gorski, 1990) and have been 
influenced by theories within socio-cognitive and behavioural psychology (Connors et al., 
1996). This review identified two different streams of theories.  
Theories from the first stream have developed from Pavlov’s theory of classical 
conditioning from the late 1890s. These theories posit that relapse is a result of cues which 
trigger withdrawal symptoms (i.e. the drug’s biochemical interaction with the individual’s 
body). Goldstein (1978) observed that relapse was dependent upon a person’s genetic 
makeup and suggested this was why some developed a dependency, and some did not. Later, 
Dejong (1994) proposed that relapse resulted from the individual’s ‘physical, psychological 
or social dysfunction’ prior to drug use (p. 687). Contemporary theories now understand 
relapse as a result of neurobiological deficits. For instance, Christiansen et al. (2015) found 
that attentional bias2 can correlate with any current motivational state of the drug user, which 
in turn can influence relapse trajectories (see theme three). Similarly, Adinoff et al. (2016) 
proposed relapse to be the result of a lack of people's ‘capacity to make optimal decisions’ 
specifically those with long-term prospects (p. 88).  
A second stream of theories disagreed with this ‘medical’ view and emphasised the 
management of psychosocial and environmental high-risk situations (Drummond, 2001; 
Powell et al., 1993). A forerunner of these theories was Albert Bandura (1977) with his work 
on self-efficacy and social learning theory, from which Marlatt (1985) developed the classic 
relapse prevention model. Marlatt suggested that unpleasant feelings of guilt and self-blame, 
 
2 Attentional bias is the acute awareness of some things while simultaneously not being aware of 
others (Cherry, 2019) 
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all of which can result from violating the commitment to abstinence, can be numbed through 
relapse behaviour (Marlatt and Witkiewitz, 2004; Donovan and Witkiewitz, 2012). This 
theory was further advanced by Vaillant (1988), who found that relapse occurs mainly 
because of non-pharmacological factors, such as unemployment, social exclusion at a young 
age, desire for gratification and the pressure to conform to cultural norms (i.e. going to pubs 
or having drug-using friends). Other studies have confirmed this view. For instance, Wallace 
(1992) found that relapse could serve to reinforce a user’s feeling state (e.g. euphoria; relief 
of pain), and Khantzian (2011) added that relapse could serve as a protective function by 
helping the user ‘escape’ from an unwanted reality.  
Theme three: associative factors. The studies reviewed identified risks associated 
with relapse and other factors which are protective of relapse. These risk and protective 
factors occur at two ecological levels, namely, at the individual and social level. The 
individual level is comprised of factors associated with relapse in neurological, 
psychological, physiological and biological dimensions. Factors occurring at a social 
ecological level include relationships, history of use, treatment and work/housing dimensions. 
In this review, these associative factors are grouped into risk and protective factors under the 
ecological level in which they occur and are categorised below if they are associated with 
more than five reviewed articles. 
Risk factors at the individual level were referenced in 70 articles, including impulsive 
decision-making without regard to the long-term consequences in 7 studies; deficits in 
neurocognitive functioning in 7 articles; damage to brain structure and functioning in 8; 
difficulty in emotion/affect regulation in 9; history of, or current mental health issues in 9; 
craving and withdrawal symptoms in 8; stressful life events in 9; male gender in 5; and being 
of young age also in 5 studies. Risk factors at the social level were referenced in 50 articles, 
including peer pressure to quit or maintain recovery in 6 studies; feeling excluded or 
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disconnected from family and friends in 7 articles; unstable housing or homelessness in 6; 
unemployment in 5; having had more than three attempts to recover and having experienced 
an unsupportive therapeutic relationship in treatment in 5 studies; long history and severity of 
drug use in 5; and poly-drug3 use or drug substitution also in 5 articles.  
Protective factors at the individual level were referenced in 17 articles, including 
motivation and desire to change in 10 studies. Protective factors at the social level were 
referenced in 20, including spirituality and a sense of connectedness in 7 studies, and setting 
boundaries and keeping a busy/structured lifestyle in 8 studies. 
These results indicate an emphasis in the literature on promoting and measuring risk 
factors over resiliency, resources and assets which help protect against relapse.  
 Theme four: treatment approaches. The studies reviewed indicated a common steer 
towards a provider-led treatment approach and a user-led treatment approach. Of these two, 
the dominant stream focussed on interventions that were exclusively administered by the 
service provider (i.e. a provider-led approach). Such interventions mainly targeted 
physiological aspects and required the service user to regularly visit provider sites. One such 
intervention was pharmacotherapy. This intervention aims to inhibit relapse by treating 
chemical imbalances or neurocognitive impairments. Numerous studies (Dackis et al., 2003; 
Carroll et al., 2004; Oliveto et al., 2011) have investigated prescription drugs, including 
naltrexone, buprenorphine and methadone for opiate dependency, and disulfiram, modafinil, 
sertraline and propranolol for cocaine dependency. Kantak (2003) argued for the use of 
medications as ‘anti-relapse vaccines’ in addition to traditional (non-pharmaceutical) 
treatment interventions. Additionally, several preclinical trials focussed on preventing relapse 
by treating glutamate imbalance (LaRowe et al., 2013; D'Souza, 2015; Berridge and 
 
3 For a discussion around the causal effects of poly-drug use on relapse, please see Williamson et al. 
(2006).    
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Robinson, 2016; Levi Bolin et al., 2017). Within this stream of approaches, the research 
focus has recently shifted towards treating relapse as a neurological illness. For instance, 
Chen, Li et al. (2019) found that administering deep brain stimulation to heroin-dependent 
participants decreased the likelihood for future relapses. Additionally, recent studies 
recommend that treatment facilities monitor clients’ biomarkers to identify those at particular 
risk for relapse. Such biomarkers for relapse included altered white matter integrity (Li et al., 
2016), cortisol levels or other stress responses (Fatseas et al., 2011), serum brain-derived 
neurotrophic factor (BDNF) (D’Sa et al., 2011) as well as amygdala-connectivity functioning 
(McHugh et al., 2014; Gawrysiak et al., 2017). Given these shifts in treatment, the 
contemporary presumption seems to be that relapse is an indicator of a failed recovery, and as 
such should be inhibited. 
By contrast, the focus in the second stream of approaches is on equipping the service 
user to manage relapse independent of the treatment service (i.e. a user-led approach), with 
the assumption that relapse forms part of the recovery process. These approaches include 
interventions which can be carried out by the service users themselves and which also address 
the users’ environments. Studies in this stream focussed on the development of employment 
skills, relationships, and time-management (Sánchez-Hervás et al., 2012). Here, studies 
included approaches in which clinicians aimed to educate the user on how to enhance their 
self-belief and positive thinking skills (see Bradley et al., 1992), as well as promoting habit 
and lifestyle shifts. The latter entails helping the service user disconnect from their previous, 
drug-using environments, and to forge new, non-drug-using habits (Dejong, 1994). More 
recently, such literature has focussed on mindfulness-based relapse prevention (MBRP) 
approaches. Zemestani and Ottaviani (2016) found that MBRP was not only simple to 
implement, but also effective in reducing a range of risk factors, including traumatic stress, 
anxiety and depression. These results were later confirmed by Bowen et al. (2017) who added 
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that MBRP enhanced service users’ self-efficacy because most of the participants were able 
to engage in the process and were thus empowered to practice independent of the treatment 
facility. The literature which aligns with this stream assumes that relapse will occur and 
therefore focusses on teaching service users how to manage their recovery independent of the 
treatment provider.  
Discussion  
This review applied Arksey and O’Malley’s (2005) framework to map the scope, 
distribution and topic trends relating to the understanding of human drug relapse in the peer-
reviewed literature. Findings from the numerical analysis show an increasing focus on the 
topic of relapse within the past decade. This increase may reflect the change in practice that 
took place in 2010. Prior to 2010, substance misuse was mainly dealt with by ‘acute 
biopsychosocial care and symptom reduction’ (Kelly and White, 2010, pg. 304) and little 
consideration was given to the risk period after treatment. Therefore, relapse was not yet 
understood to be taken care of by service providers and was also no yet seen as the 
responsibility of the service user. However, 2010 marked a time when addiction scientists 
began to understand addiction as a chronic condition which required maintenance care (Kelly 
and White, 2010), and the empowerment of service users in the management of their own 
recovery. Given the high relapse rates in the service-led approaches (Hser et al., 1998), the 
shift in emphasis led to the introduction of models like recovery management (RM) and 
recovery-oriented systems of care (ROSC). These models gave greater weight to the period 
after acute treatment and, with that, to relapse. Since this shift, the prevention and 
management of relapse has become a part of the care and support that service providers offer, 
and therefore may have motivated more research on relapse. 
This review also identified a geographically narrow focus on relapse. Most opiate and 
crack cocaine relapse understandings were derived from the USA and the UK, whereas only 
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one study was conducted in Africa (Appiah et al., 2018) and one in South America (Lopes-
Rosa et al., 2017). In addition, only one study in this review, dated 1992, has focussed on 
crack cocaine relapse.  
Findings from the thematic analysis demonstrate that issues around relapse definitions 
remain and impact on how relapse is treated and researched. Although practitioners advocate 
that the definitions should be left open to interpretation, one overarching relapse definition 
dominates in practice. The reason for this dilemma is the critique that having only one 
definition could foster stigma by assuming relapse to happen regardless of service user and 
provider efforts. The reverse is true for research. To make relapse measurable, researchers 
have used multiple definitions. This has attracted criticism around the validity and 
comparability of findings and led researchers to recommend the use of one, overarching 
relapse definition. Such a lack of agreement between relevant professional implies that the 
current dominance of NIDA’s relapse definition may be influenced by NIDA’s political 
stance on addictions research and practice, rather than on its scientific merit. Additionally, the 
studies indicate that relapse definitions have mainly been established by scientific 
perspectives rather than by frontline worker accounts. McKeganey et al. (2004) have long 
argued that the perspectives of frontline workers and service users must be considered in 
future research, to enhance the accuracy and validity of addiction-related topics. Additionally, 
this review has identified that working definitions of relapse were not made explicit in over 
60% of the studies reviewed. As working definitions of the phenomenon under investigation 
should be provided in all research (Ashford et al., 2019), the validity and generalisability of 
the current evidence base may be questioned.  
This review has further shown that contemporary relapse theories have developed 
from early notions in psychology and are divided into two streams with the more dominant 
stream focussing on illness (relapse prevention and inhibition), and the other focussing on 
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wellness (relapse management and coping). As contemporary relapse theories have 
predominantly been developed through clinical and neuroscientific evidence (e.g. biological 
relapse profiles (Sinha, 2011), biomarker (Chen, Li et al., 2019), mathematical formulas 
(Tasic et al., 2018)), opiate and crack cocaine relapse research is ripe for inter-disciplinary 
investigations. Additionally, several of these studies on biomarkers have provided 
recommendations which might be hard to implement. For instance, researchers have 
suggested that fMRI machines be used in clinical practice (e.g. in detox facilities) to identify 
those at risk early on (Gawrysiak et al., 2017). However, drug services and treatment 
facilities across Europe, particularly in the UK, and North America struggle with recurrent 
budget cuts (Rhodes, 2018, BBC News England), making such recommendations unfeasible.  
This review revealed that the literature on risk factors for relapse dominates over 
literature on protective factors for relapse. While knowledge about risk factors is invaluable, 
there remains less knowledge on how users can effectively protect themselves from relapse 
experiences. This finding is however not surprising, given that the disease model remains the 
dominant theoretical lens through which relapse is understood. A focus on risk factors over 
protective factors can portray the service user as a victim of their disease and helpless without 
the treatment provider, which is the premise for the disease model. Pickard (2017) has argued 
that the disease model is ‘neither credible in the face of the evidence, nor helpful in so far as 
it disempowers addicts’ (p. 176), as have many others (see Heather et al., 2018). This 
argument is supported by this review’s findings on associative factors, as many of these did 
not relate to physical disease (e.g. lack of social support; childhood trauma). Stigmatisation of 
the drug service user community is fostered by overlooking the evidence that relapse is in 
fact, not only related to a physical disease, but also to psychosocial factors. Based on these 
findings, it can be argued that whatever ‘comfort’ or political advantage the adherence to the 
disease model of addiction brings, it ultimately stalls scientific advancement in the field 
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(Heather et al., 2018). This view concurs with Pickard (2017), who challenges experts to 
consider asking ‘what our part is, as a society, in drug use and addiction?’ (p. 177). 
The presumption that relapse is based on physical health issues was also mirrored in 
the literature on relapse treatment approaches. Treatment interventions which are 
administered by the provider dominate over interventions which can be carried out by the 
service user, thereby indicating an overall emphasis on harm minimization and prevention 
rather than on self-maintained health and wellness. This emphasis is supported by the World 
Health Organization, as evidenced in a recent statement which suggests that ‘prevention is the 
best means of fighting the problem [of illicit drug abuse]…rapid rises in drug-related deaths 
and in infectious diseases related to drug abuse…show the need for programmes to minimize 
risk’ (WHO, 2019).  
This review demonstrates that most of our relapse understanding is derived from 
quantitative and experimental research designs. Merely 3% of the literature in this review 
used qualitative interviews. One reason for such a lack of qualitative inquiry could be how 
relapse is currently being understood. The findings on definitions and treatment approaches 
indicate that the scientific community seems to primarily understand relapse as a 
physiological issue and therefore a responsibility of the clinician, which is best 
explored/assessed by experts rather than through participants’ accounts. Another possible 
reason could be lack of ease of access to drug service users as participants for relapse studies. 
Given the high relapse rates and the general criticism around self-report data (see Chan, 
2009), accessing drug service users who are stable enough to be interviewed and to provide 
‘valid’ self-report data could be challenging. Nevertheless, this highlights a fundamental need 
to explore relapse from a service user and provider viewpoint.  
The findings of this review have clearly demonstrated that relapse into drug misuse is 
mainly being understood on an individualistic level, that is, how the biological or 
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physiological state of the individual is impacted by, and can impact, relapse into substance 
misuse. Reducing the understanding of relapse primarily to a biological phenomenon 
provides both limitations and opportunities – limitations due to a failure to appreciate the 
importance of psychosocial factors and opportunities for enhanced funding from 
commissioners who favour the more biological approaches. However, when a person in 
recovery relapses back into drug misuse, following their housing situation becoming unstable 
and their close friend passing away, it is difficult to discern whether this was due to 
heightened cortisol levels or the issues faced within their social context, or both. It would be 
unwise to understand a complex phenomenon such as relapse into drug misuse independently 
of the wider social and political context (Spanagel and Mann, 2006; Best, 2012). 
Bronfenbrenner’s (1992) ecological systems theory, for example, has offered a framework to 
understand how social interaction is embedded in, and interconnected with, social systems 
and their sub-systems. International research helps us shed light on the factors influencing 
outcomes, but this research must be interpreted within the given socio-political context. For 
instance, the USA and the UK have different health and social care systems which may 
reflect how these nations approach issues like substance misuse. To gain a more complete 
picture of relapse into drug misuse, we must consider the wider context, including how it 
impacts the relationship between an individual’s microsystem (i.e. biology, emotional 
system) and their mesosystem (e.g. family, treatment provider), all the while acknowledging 
their relationship to the political context (e.g. drug policy). 
Limitations 
This scoping review has several limitations. Firstly, the application of strict 
inclusion/exclusion criteria as well as the choice of search databases employed, influenced 
the range and volume of the included studies. Secondly, the language restrictions could 
explain the limited geographic coverage and cultural perspectives covered, as the focus only 
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on studies published in English may have excluded information on relapse understandings 
from other countries published in other languages. Pragmatic constraints, and in particular the 
lack of funding to translation sources, limited what was possible. Nevertheless, the inclusion 
of literature from Spanish-speaking countries (which often produce and export cocaine) and 
other countries warrants future research. Lastly, although no search restrictions were set on 
demographics, the population that the reviewed literature focussed on was limited primarily 
to adult participants (n=81). Of these 81 studies, six focussed specifically on male 
participants and two on women. Only three of the reviewed studies focussed on adolescent 
participants. Therefore, important information on relapse understandings from, for example, 
women or young people, is lacking.  
Future research 
The above limitations indicate that future research would benefit from cross-cultural 
investigations of relapse, which would enhance the accuracy and diversity of the current 
relapse evidence base. Such studies could, for example, explore how relapse is understood in 
Western compared to non-Western cultures. It would also be useful to synthesise evidence 
from literature published in languages other than English. For instance, this scoping review 
could be replicated by multi-and/or bi-lingual researchers who can scope and translate 
evidence from non-English published literature in order to make it available to English-
speaking readers. It would also be beneficial to investigate relapse in populations other than 
white male adults (e.g. young Native American people or Latina women). Additionally, 
promoting inter-disciplinary research is crucial to prevent fostering a discipline-limited 
evidence base, which would involve encouraging collaboration between researchers from 
multiple disciplines (i.e. sociology, health and wellbeing, anthropology, nursing, mental 
health, policy sciences). Examining the cost-effectiveness of the recommendations made by 
health researchers (i.e. biomarker studies), for example via advisory groups, within which 
18 
 
drug service providers could offer feedback and recommendations, would add to the 
usefulness of studies. A systematic review which assesses the quality, validity and rigour of 
the relapse evidence that has been scoped here would be beneficial. Lastly, and in particular, 
future research on relapse understandings should consider qualitative or participatory-based 
research designs in order to explore the voices and experiences of those most closely related 
to it (e.g. drug users or providers). 
Conclusion 
This review was the first to explore understandings of relapse into opiate and crack 
cocaine misuse using a scoping review methodology. Despite its limitations, this review 
captured effectively the characteristics and distribution of the literature, and identified key 
debates relating to definitions, theories, risk and protective factors and treatment modalities. 
With opiates and crack cocaine-related issues becoming more prevalent across the globe, it 
has never been more important to engage in drug relapse research, which therefore needs to 
grow more diverse, inter-disciplinary and user-centred in perspective so as to respond to the 
challenges ahead. 
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